Clinical Convergence®: Changing Perspectives—Fine Tuning Treatment for the Relapsed Refractory Patient with Chronic Myeloid Leukemia

Activity Overview

This Clinical Convergence ® activity addresses new developments in the treatment of relapsed/refractory CML with a focus on appropriate therapeutic decision making and monitoring in the second- and third-line setting. The program features a clinical case vignette to engage the learner and facilitate acquisition and integration of new skills and behaviors, as well as a patient encounter to provide unique perspectives on aspects of treatment selection, adherence, monitoring requirements, and adverse event management. A non-certified practice aid is included as a resource for provider-patient discussions on potential side effects.

0.75 CE Credit(s)
Expires: June 14, 2022

Target Audience

This activity is intended for medical oncologists, hematologists, NPs, PAs, nurses, and other HCPs engaged in the care of patients with chronic myeloid leukemia (CML).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Employ key data on tyrosine kinase inhibitors (TKIs) when treating and monitoring patients with relapsed or refractory CML
  • Select appropriate therapy for patients with CML refractory to 2nd generation agents
  • Integrate strategies to monitor and manage potential adverse effects, such as cardiotoxicity, that may result in cross-intolerance to TKIs in patients with CML

Activity Faculty

Cortes

Jorge Cortes, MD (Course Director)

Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, GA

Shoukier

Mahran Shoukier, MD

Hematology/Oncology Fellow
Section of Hematology/Oncology, Department of Medicine
Georgia Cancer Center at Augusta University
Augusta, GA